354812-41-2 Usage
Description
1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid is a complex organic compound with a unique molecular structure that features a quinoline core, a cyclopropyl group, a diazabicyclo nonane moiety, a fluorine atom, a methoxy group, and a carboxylic acid functional group. 1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4 -oxo-quinoline-3-carboxylic acid is characterized by its potential reactivity and versatility in chemical reactions, making it a valuable component in various synthetic and pharmaceutical applications.
Uses
Used in Organic Synthesis:
1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid is used as a key intermediate in organic synthesis for the preparation of a variety of complex organic molecules. Its unique structure allows for selective functionalization and the formation of new chemical bonds, facilitating the synthesis of target compounds with desired properties.
Used in Pharmaceutical Intermediates:
In the pharmaceutical industry, 1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid serves as an important building block for the development of new drugs. Its structural features can be exploited to design and synthesize bioactive molecules with potential therapeutic applications, such as antimicrobial, antiviral, or anticancer agents.
Used in Laboratory Research and Development:
1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid is utilized in laboratory research and development processes to explore its chemical properties, reactivity, and potential applications in various fields. Researchers can use this compound to investigate new reaction pathways, develop innovative synthetic methods, and discover novel compounds with unique properties.
Used in Chemical Production Processes:
In the chemical production industry, 1-cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid is employed as a crucial intermediate in the synthesis of various specialty chemicals. Its presence in the production process can enhance the efficiency, yield, and quality of the final products, contributing to the advancement of the chemical industry.
Synthesis
1.Load a mixture of corresponding acid derivative (3.5 mmol) with piperazine (5.25mmol) in a small flask fitted with a micro condenser, placed in the microwave reactor.2. Irradiate the reaction mixture for 25 minutes at 150°C under solvent free conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 354812-41-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,5,4,8,1 and 2 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 354812-41:
(8*3)+(7*5)+(6*4)+(5*8)+(4*1)+(3*2)+(2*4)+(1*1)=142
142 % 10 = 2
So 354812-41-2 is a valid CAS Registry Number.
354812-41-2Relevant articles and documents
Preparation method of moxifloxacin
-
Paragraph 0039-0042, (2021/05/08)
The invention provides a preparation method of moxifloxacin, which comprises the following steps: taking 1-cyclopropyl-6, 7-difluoro-8-methoxy-4-oxo-1, 4-dihydro-3-quinolinecarboxylic acid and (S, S)-2, 8-diazabicyclo[4.3. 0] nonane as raw materials, in an organic solvent, in the presence of an acid-binding agent, and carrying out condensation reaction by taking the tri-coordinated boride cation-chloroaluminate ionic liquid as a catalyst to prepare moxifloxacin. The structural formula of the tri-coordinated boride cation-chloroaluminate ionic liquid is BX2L, X is a halogen atom, and L is selected from 4-picoline (4-pic), imidazole (mim) and dimethylacetamide (DMA) ligands. The preparation method of moxifloxacin has the advantages of simple reaction steps, high yield, high product purity, mild conditions and easiness in industrial production.
Nano-Fe3 O4@ZrO2-SO3 H as highly efficient recyclable catalyst for the green synthesis of fluoroquinolones
Nakhaei, Ahmad,Ramezani, Shirin,Shams-Najafi, Sayyed Jalal,Farsinejad, Sadaf
, p. 739 - 746 (2018/09/26)
Nano-Fe3 O4 @ZrO2-SO3 H (n-FZSA), was utilized as a magnetic catalyst for the synthesis of various fluoroquinolone compounds. These compounds were prepared by the direct amination of 7-halo-6-fluoroquinolone-3-carboxylic acids with piperazine derivatives and (4aR,7aR)-octahydro-1H-pyrrolo[3,4-b] pyridine in water. The results showed that n-FZSA exhibited high catalytic activity towards the synthesis of fluoroquinolone derivatives, giving the desired products in high yields. Furthermore, the catalyst was recyclable and could be used at least seven times without any discernible loss in its catalytic activity. Overall, this new catalytic method for the synthesis of fluoroquinolone derivatives provides rapid access to the desired compounds in refluxing water following a simple work-up procedure, and avoids the use of organic solvents.
Fluorescence quenching study of moxifloxacin interaction with calf thymus DNA
Lv, Yun-Kai,Li, Pan,Jiao, Miao-Lun,Liu, Bao-Sheng,Yang, Chao
, p. 202 - 209 (2014/04/03)
Moxi oxacin (MOX) is a fourth-generation synthetic uoroquinolone antibacterial agent with many important therapeutic properties. Fluorescence quenching was used to study the interaction of MOX with calf thymus DNA (ct- DNA) in aqueous solution. The intercalative binding mode and a static quenching mechanism were conflrmed by the Stern-Volmer quenching rate constant (Kq) of 3.48 × 1011 M-1 s-1 at 298 K. The thermodynamic parameters (δH = -118.4 KJ mol-1 and δS = -299.4 J mol-1 K-1) were calculated at different temperatures, and they indicate that the main forces between MOX and ct-DNA are hydrogen bonding and Van der Waals force. We proved at the same time the presence of one single binding site on ct-DNA, and the binding constant is 1.28 × 105 M-1 at physiological pH. The results may provide a basis for further studies and clinical application of antibiotics drugs. Tubitak.
